

Minimal Ecstasy Use Linked to Cognitive Deficits

BY BRUCE JANCIN
Denver Bureau

VIENNA — Even a few low doses of the drug ecstasy were associated with a decline in verbal memory function in a unique prospective study of first-time users, Thelma Schilt said at the annual congress of the European College of Neuropsychopharmacology.

Carriers of the methionine allele of the catechol-O-methyltransferase (COMT) gene polymorphism proved far more sensitive to this adverse drug effect than were people who possessed the valine allele, added Ms. Schilt of the Amsterdam Institute for Addiction Research and the University of Amsterdam.

Ecstasy (3,4-methylenedioxymethamphetamine), also known as MDMA, is an inexpensive illicit recreational drug that's



'The changes are small. You would not notice in everyday life that their memory had declined.'

MS. SCHILT

popular in the dance club/rave scene. Users report feelings of happiness and connection to others. Animal studies suggest that ecstasy is neurotoxic, producing long-term damage to the distal axons of serotonergic neurons.

Cognitive deficits have been documented in recreational users. However, such studies have either been cross-sectional or retrospective, and have mostly involved heavy users of ecstasy and multiple other potentially confounding drugs, including cocaine, alcohol, cannabis, and amphetamines.

For this reason, Ms. Schilt and her coinvestigators performed a prospective observational cohort study in 188 ecstasy-naive subjects as part of the larger Netherlands XTC Toxicity Study. Participants, whose mean age was 22 years, were recruited at places such as dance clubs and university campuses. Participants had to indicate an interest in trying ecstasy in the future, have a history of only minimal exposure to other recreational drugs, and undergo baseline neuropsychologic testing and brain-imaging studies.

During 11 months of follow-up, 58 subjects took ecstasy. Their usage was modest: a mean cumulative dose of 3.2 tablets and a median of 1.5. They underwent neuropsychologic testing roughly 12 weeks after their most recent use of the drug, as did a matched group of 60 subjects who remained persistently ecstasy naive. The participants were queried about drug use during follow-up, and underwent drug screening to validate their self-reported minimal use of other drugs.

At baseline, the two groups had similar neuropsychologic test scores. However, at follow-up the ecstasy users had significantly lower scores on immediate and delayed verbal recall and verbal recognition. Other cognitive domains were unaffected.

"The changes are small. You would not notice in everyday life that their memory had declined," Ms. Schilt stressed.

Nonetheless, the test results suggest even a low cumulative dose of ecstasy could be neurotoxic. Further follow-up will show whether the deficits remain after longer periods of abstinence. Also worthy of further study is the possibility that ecstasy accelerates the decline in verbal memory that's part of the normal aging process. Answers to these questions will

have a bearing on ongoing clinical studies exploring the use of MDMA to facilitate psychotherapy, she continued.

Because ecstasy's pleasurable effects are attributable to a boost of serotonin in the brain, it was initially hypothesized that the serotonin transport promoter gene was involved in the drug's adverse effects upon memory. When other investigators demonstrated that that was not the case, Ms. Schilt and coinvestigators decided to study the effects of COMT gene

polymorphisms in their subjects. They found the neuropsychologic test abnormalities associated with ecstasy use were most pronounced in people homozygous for the methionine or met allele.

This finding makes sense, Ms. Schilt explained, because the met allele is associated with low COMT activity and thus relatively high synaptic dopamine levels.

The Netherlands XTC Toxicity Study is funded by the Netherlands Organization for Health Research and Development. ■

Treat With the Body in Mind



CHOOSE **GEODON**[®]
(ziprasidone HCl) Oral Capsules

GEODON is indicated for the treatment of acute manic or mixed episodes associated with bipolar disorder and for the treatment of schizophrenia.

Elderly patients with dementia-related psychosis treated with atypical antipsychotic drugs are at an increased risk of death compared to placebo. GEODON is not approved for the treatment of patients with dementia-related psychosis.

GEODON is contraindicated in patients with a known history of QT prolongation, recent acute myocardial infarction, or uncompensated heart failure, and should not be used with other QT-prolonging drugs. GEODON has a greater capacity to prolong the QT_c interval than several antipsychotics. In some drugs, QT prolongation has been associated with torsade de pointes, a potentially fatal arrhythmia. In many cases this would lead to the conclusion that other drugs should be tried first.

As with all antipsychotic medications, a rare and potentially fatal condition known as neuroleptic malignant syndrome (NMS) has been reported with GEODON. NMS can cause hyperpyrexia, muscle rigidity, diaphoresis, tachycardia, irregular pulse or blood pressure, cardiac dysrhythmia, and altered mental status. If signs and symptoms appear, immediate discontinuation, treatment, and monitoring are recommended.

Please see brief summary of prescribing information on adjacent page.

Prescribing should be consistent with the need to minimize tardive dyskinesia (TD), a potentially irreversible dose- and duration-dependent syndrome. If signs and symptoms appear, discontinuation should be considered since TD may remit partially or completely.

Hyperglycemia-related adverse events, sometimes serious, have been reported in patients treated with atypical antipsychotics. There have been few reports of hyperglycemia or diabetes in patients treated with GEODON, and it is not known if GEODON is associated with these events. Patients treated with an atypical antipsychotic should be monitored for symptoms of hyperglycemia.

Precautions include the risk of rash, orthostatic hypotension, and seizures.

The most common adverse events associated with GEODON in bipolar mania were somnolence, extrapyramidal symptoms, dizziness, akathisia, and abnormal vision.

In short-term schizophrenia trials, the most commonly observed adverse events associated with GEODON at an incidence of ≥5% and at least twice the rate of placebo were somnolence and respiratory tract infection.

In short-term schizophrenia clinical trials, 10% of GEODON-treated patients experienced a weight gain of ≥7% of body weight vs 4% for placebo.